The company has secured the differentiated R&D competence and has received the U.S.
FDA approval for its new drugs for the first time in Korea.
Based on our superior biotechnology and R&D capabilities accumulated since 1980s, we
have been successful in developing a variety of original products including Korea's
first growth hormone for children, new drugs for diabetes, etc. At the same time, we
have continuously expanded our
competitive edge through cooperation with global pharmaceutical companies.
